Aytu BioPharma vs Zevra Therapeutics
AYTU and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AYTU and ZVRA compare
Zevra Therapeutics is the larger company, worth 19 times as much as Aytu BioPharma ($558M against $28.9M).
Zevra Therapeutics grew revenue faster over the last twelve months (119% versus −13.3% for Aytu BioPharma).
Zevra Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.8% compared with −24.8% at Aytu BioPharma.
Zevra Therapeutics scores higher on the StockData Score (15 against 9 for Aytu BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AYTU | ZVRA |
|---|---|---|
| Size and price | ||
| Market cap | $28.9M | $558M |
| Share price | $2.66 | $9.40 |
| Change, 1 year | 27.3% | 5.9% |
| Change, 5 years | −93.2% | 16.8% |
| Beta (5Y) | −0.05 | 1.16 |
| Employees | 76 | 61 |
| StockData Score | ||
| Total score | 9 | 15 (better) |
| Valuation score | 3 | 3 |
| Growth score | 0 | 3 (better) |
| Performance score | 3 | 3 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 10.1× |
| P/S | 0.5× (better) | 4.1× |
| P/B | 0.8× (better) | 2.6× |
| EV/EBITDA | – | 4.0× |
| P/FCF | 8.9× (better) | 17.1× |
| FCF yield | 11.3% (better) | 5.8% |
| Fair value | $8.97 | $23.57 |
| Margin of safety | 70.4% (better) | 60.1% |
| Growth | ||
| Revenue growth (TTM) | −13.3% | 119% (better) |
| Revenue growth, 5Y average | −2.6% | 51.6% (better) |
| Net income growth (TTM) | – | 2104% |
| Profitability | ||
| Gross margin | 64.0% | 95.5% (better) |
| Operating margin | −14.4% | 60.5% (better) |
| Net margin | −24.8% | 42.8% (better) |
| FCF margin | 5.6% | 24.0% (better) |
| Return on equity | −52.6% | 34.8% (better) |
| Return on invested capital | −63.5% | – |
| Financial health | ||
| Debt / equity | 0.31 (better) | 0.00 |
| Net debt / EBITDA | – | −2.64 |
| Interest coverage | −4.4× | 14.4× (better) |
| Current ratio | 1.13 | 5.17 (better) |
| Altman Z-score | −4.02 | 4.35 (better) |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 45.3% | 78.5% |
| Held by insiders | 15.1% | 1.2% |
| Insider net buying, 12 months | – | −$2.5M |
| Short interest, % of float | 3.3% | 11.2% |
Go deeper
- AYTU stock overview
- AYTU income statement
- AYTU valuation and score
- ZVRA stock overview
- ZVRA income statement
- ZVRA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.